Citi Pharma Limited has approved the acquisition of 100% shareholding in Pakheim International Pharmaceuticals (Private) Limited as part of its broader expansion plan in the pharmaceutical sector.

In a notice to the Pakistan Stock Exchange on May 6, 2026, the company said its Board of Directors has cleared the proposed transaction, which also includes Pakheim’s assets, manufacturing facility, licenses, and ongoing operations. The deal will proceed subject to regulatory approvals and completion of due diligence.

Pakheim International Pharmaceuticals operates an established manufacturing plant and holds multiple DRAP-registered products. Citi Pharma said the acquisition is aimed at increasing its production capacity, expanding its product range, and strengthening its market presence locally and abroad.

The company noted that Pakheim currently generates annual revenue of around Rs. 500 million. It expects the acquisition to create operational synergies, improve production efficiency, and support future growth in both domestic and international markets.

Citi Pharma has set a long-term target of reaching Rs. 5 billion in revenue over the next five years, driven by portfolio expansion, improved distribution networks, and continued investment in manufacturing and product development.

The company further stated that the transaction will be financed through a mix of internal cash resources and available banking facilities, with payments scheduled to be completed by December 31, 2026.

Citi Pharma also highlighted that the acquisition will strengthen its active pharmaceutical ingredients (API) segment, as the acquired facility will source APIs directly from Citi Pharma, helping improve capacity utilization and boosting API sales.